Spruijt J, Vierhout M, Verstraeten R, Janssens J, Burger C (2003) Vaginal electrical stimulation of the pelvic floor: a randomized feasibility study in urinary incontinent elderly women. JAMA 288(18):2293–2299įitz FF, Resende AP, Stupp L, Sartori MG, Girao MJ, Castro RA Biofeedback for the treatment of female pelvic floor muscle dysfunction: a systematic review and meta-analysis.

doi:CD001407 10.1002/14651858.CD001407īurgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd LK (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ, de Bie RA, van Waalwijk van Doorn ES (2001) Pelvic floor muscle training for urinary incontinence in women. Weatherall M (1999) Biofeedback or pelvic floor muscle exercises for female genuine stress incontinence: a meta-analysis of trials identified in a systematic review. doi: 10.1007/s0040-4ĭe Kruif YPVE (1996) Pelvic floor muscle exercise therapy with myofeedback for women with stress urinary incontinence: a meta-analysis. doi: 10.1002/nau.10153ĭannecker C, Wolf V, Raab R, Hepp H, Anthuber C (2005) EMG-biofeedback assisted pelvic floor muscle training is an effective therapy of stress urinary or mixed incontinence: a 7-year experience with 390 patients. Minerva Ginecol 60(6):529–541īo K (2003) Pelvic floor muscle strength and response to pelvic floor muscle training for stress urinary incontinence. doi: 10.1002/2ĭi Benedetto P, Coidessa A, Floris S (2008) Rationale of pelvic floor muscles training in women with urinary incontinence. Device usability was very good.ĭumoulin C, Hay-Smith J (2010) Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Twelve weeks of InTone usage resulted in significant objective and subjective reductions in UI. Device usability was good, with a median SUS of 86.3 and a median expected use of 107 % (33–140 %). After 12 weeks of InTone therapy, median UDI6 and IIQ7 scores improved from 50.0 to 29.2 ( p 50 % reduction in daily pad usage and PWT. Thirty-three women were enrolled five patients withdrew and were excluded.

Usability was assessed with a device-usage log and the System Usability Scale (SUS), which evaluates patients’ global impression of usability. Efficacy was assessed by comparing 12-week results to baseline values using chi-square and Wilcoxon rank-sum tests.

Patients were assessed at baseline and monthly with symptom questionnaires, bladder diaries. InTone was used 5–6 days a week for 12 weeks. Women with UI (stress, urge, mixed) were recruited for this pilot trial. The purpose of this study was to assess its efficacy and usability for treating urinary incontinence (UI). InTone TM (InControl Medical) is a nonimplanted vaginal device providing biofeedback and electrical stimulation of pelvic floor muscles.

Incontrol medical device